Home / Investors / Press Releases

CymaBay Therapeutics to Present at Two Investor Conferences in April

Download PDF

NEWARK, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the H.C. Wainwright & Co. 1st Annual NASH Investor Conference, being held April 3, 2017 at the St. Regis Hotel in New York City, and the BioCentury Future Leaders in the Biotech Industry Conference, being held April 7 at the Millennium Broadway Hotel & Conference Center in New York City.

1st Annual NASH Investor Conference
Date: Monday, April 3
Time: 11:40am Eastern Time
Location: St. Regis Hotel, New York City
BioCentury Future Leaders in the Biotech Industry Conference
Date: Friday, April 7
Time: 1:30pm Eastern Time
Location: Millennium Broadway Hotel & Conference Center, New York City, NY

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.  Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

For additional information about CymaBay visit

Sujal Shah    
CymaBay Therapeutics, Inc.  
(510) 293-8800 

Hans Vitzthum
LifeSci Advisors, LLC

Primary Logo

Source: CymaBay Therapeutics, Inc.